The safety of levetiracetam

Deepa Sirsi, Joseph E. Safdieh

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged ≥ 4 years. It was also approved as adjunctive therapy in the treatment of adults and adolescents aged ≥ 12 years with juvenile myoclonic epilepsy. A parenteral intravenous formulation has recently become available allowing for its use when oral administration is temporarily not feasible. Available literature has demonstrated and supported that levetiracetam has an acceptable safety profile and this review discusses the safety profile of levetiracetam, with attention to special populations. The most common adverse effects are somnolence, asthenia and dizziness, which usually appear early after initiation of levetiracetam therapy and generally resolve without medication withdrawal. The most serious adverse effects are behavioral in nature and are more common in children and in patients with a prior history of behavioral problems.

Original languageEnglish (US)
Pages (from-to)241-250
Number of pages10
JournalExpert Opinion on Drug Safety
Volume6
Issue number3
DOIs
StatePublished - May 2007

Fingerprint

etiracetam
Safety
Juvenile Myoclonic Epilepsy
Asthenia
Dizziness
Anticonvulsants
Oral Administration
Seizures
Therapeutics

Keywords

  • Adverse effects
  • Behavioral effects
  • Keppra
  • Levetiracetam
  • Safety
  • Side effects

ASJC Scopus subject areas

  • Pharmacology

Cite this

The safety of levetiracetam. / Sirsi, Deepa; Safdieh, Joseph E.

In: Expert Opinion on Drug Safety, Vol. 6, No. 3, 05.2007, p. 241-250.

Research output: Contribution to journalArticle

Sirsi, Deepa ; Safdieh, Joseph E. / The safety of levetiracetam. In: Expert Opinion on Drug Safety. 2007 ; Vol. 6, No. 3. pp. 241-250.
@article{5e42c059be6b4fb18da6cd2005a266fa,
title = "The safety of levetiracetam",
abstract = "Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged ≥ 4 years. It was also approved as adjunctive therapy in the treatment of adults and adolescents aged ≥ 12 years with juvenile myoclonic epilepsy. A parenteral intravenous formulation has recently become available allowing for its use when oral administration is temporarily not feasible. Available literature has demonstrated and supported that levetiracetam has an acceptable safety profile and this review discusses the safety profile of levetiracetam, with attention to special populations. The most common adverse effects are somnolence, asthenia and dizziness, which usually appear early after initiation of levetiracetam therapy and generally resolve without medication withdrawal. The most serious adverse effects are behavioral in nature and are more common in children and in patients with a prior history of behavioral problems.",
keywords = "Adverse effects, Behavioral effects, Keppra, Levetiracetam, Safety, Side effects",
author = "Deepa Sirsi and Safdieh, {Joseph E.}",
year = "2007",
month = "5",
doi = "10.1517/14740338.6.3.241",
language = "English (US)",
volume = "6",
pages = "241--250",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The safety of levetiracetam

AU - Sirsi, Deepa

AU - Safdieh, Joseph E.

PY - 2007/5

Y1 - 2007/5

N2 - Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged ≥ 4 years. It was also approved as adjunctive therapy in the treatment of adults and adolescents aged ≥ 12 years with juvenile myoclonic epilepsy. A parenteral intravenous formulation has recently become available allowing for its use when oral administration is temporarily not feasible. Available literature has demonstrated and supported that levetiracetam has an acceptable safety profile and this review discusses the safety profile of levetiracetam, with attention to special populations. The most common adverse effects are somnolence, asthenia and dizziness, which usually appear early after initiation of levetiracetam therapy and generally resolve without medication withdrawal. The most serious adverse effects are behavioral in nature and are more common in children and in patients with a prior history of behavioral problems.

AB - Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged ≥ 4 years. It was also approved as adjunctive therapy in the treatment of adults and adolescents aged ≥ 12 years with juvenile myoclonic epilepsy. A parenteral intravenous formulation has recently become available allowing for its use when oral administration is temporarily not feasible. Available literature has demonstrated and supported that levetiracetam has an acceptable safety profile and this review discusses the safety profile of levetiracetam, with attention to special populations. The most common adverse effects are somnolence, asthenia and dizziness, which usually appear early after initiation of levetiracetam therapy and generally resolve without medication withdrawal. The most serious adverse effects are behavioral in nature and are more common in children and in patients with a prior history of behavioral problems.

KW - Adverse effects

KW - Behavioral effects

KW - Keppra

KW - Levetiracetam

KW - Safety

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=34248584562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248584562&partnerID=8YFLogxK

U2 - 10.1517/14740338.6.3.241

DO - 10.1517/14740338.6.3.241

M3 - Article

VL - 6

SP - 241

EP - 250

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -